Holen Sie sich die Stockscreener-App
15.04
6.29%
0.89
Handel nachbörslich:
15.13
0.09
+0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.15
Offen:
$14.57
24-Stunden-Volumen:
1.74M
Relative Volume:
1.68
Marktkapitalisierung:
$1.98B
Einnahmen:
$265.81M
Nettoeinkommen (Verlust:
$77.84M
KGV:
26.80
EPS:
0.5611
Netto-Cashflow:
$120.40M
1W Leistung:
+4.23%
1M Leistung:
+3.16%
6M Leistung:
+20.03%
1J Leistung:
+86.14%
1-Tages-Spanne:
$14.42
$15.14
1-Wochen-Bereich:
$13.52
$15.14
52-Wochen-Spanne:
$6.825
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.04 | 1.87B | 265.81M | 77.84M | 120.40M | 0.5611 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Hochstufung | Jefferies | Hold → Buy |
| 2025-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook Reveals 19.63% Potential Upside - DirectorsTalk Interviews
Tang Capital LPs tied to Aurinia (NASDAQ: AUPH) buy 900K shares - Stock Titan
Tang Capital boosts Aurinia (AUPH) stake to 9.2% ownership - Stock Titan
Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill - Stock Titan
Aurinia (AUPH) COO receives stock grants and settles taxes with shares - Stock Titan
Aurinia (NASDAQ: AUPH) CEO receives major option grant and withholds shares for taxes - Stock Titan
Aurinia (AUPH) CMO awarded new stock options and share grant - Stock Titan
Aurinia (AUPH) EVP gets stock awards and has shares withheld for taxes - Stock Titan
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" - ChartMill
GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Should Aurinia’s Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? - Yahoo Finance
Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals - Sahm
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 - Bitget
Understanding the Setup: (AUPH) and Scalable Risk - Stock Traders Daily
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
How Aurinia Pharmaceuticals Inc. stock trades during market volatilityWeekly Trade Review & AI Driven Stock Movement Reports - mfd.ru
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2025 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals (AUPH) Earnings Spike Above Revenue Challenges Profit Quality Narratives - Sahm
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results - MarketBeat
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets - Fidelity
Aurinia Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
AUPH: LUPKYNIS posted robust 2025 growth, with 2026 guidance reflecting continued momentum and market expansion - TradingView
Earnings call transcript: Aurinia Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com
AUPH: LUPKYNIS sales and net income surged in 2025, with double-digit growth expected in 2026 - TradingView
Aurinia Pharmaceuticals : Corporate Presentation (Aurinia Corporate Presentation February 2026) - marketscreener.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aurinia Results Highlight LUPKYNIS Momentum And New Aritinercept Growth Option - Yahoo Finance
Earnings Breakdown: Aurinia Pharmaceuticals Q4 - Benzinga
Q4 2025 Earnings Call - marketscreener.com
Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates - Stocktwits
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook - TipRanks
Aurinia Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
AUPH: LUPKYNIS sales and net income soared in 2025, with strong growth and robust 2026 guidance - TradingView
Aurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook - TipRanks
AURINIA PHARMACEUTICALS ($AUPH) Releases Q4 2025 Earnings - Quiver Quantitative
(AUPH) Aurinia Pharmaceuticals Expects Full Year 2026 Revenue Range $315M$325, vs. FactSet Est of $326.8M - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $1.53 - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q4 Revenue $77.1M, vs. FactSet Est of $74.7M - marketscreener.com
Aurinia Pharmaceuticals Inc announces its financial results for the fourth quarter and full year ended December 31, 2025 - Bitget
Aurinia Pharmaceuticals Inc. SEC 10-K Report - TradingView
Aurinia: Q4 Earnings Snapshot - marketscreener.com
Form 10-K Aurinia Pharmaceuticals For: Dec 31 - StreetInsider
Profit surge as Aurinia (NASDAQ: AUPH) raises 2026 LUPKYNIS outlook - Stock Titan
Earnings Summary: Aurinia Pharmaceuticals Q4 - Benzinga
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - marketscreener.com
BRIEF-Aurinia Pharmaceuticals Q4 Product Revenue USD 74.173 Million - TradingView
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):